Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
499.40    -0.60 (-0.12%)
Bid:
500.00
Ask:
501.00
Spread: 1.00 (0.20%)
Market Cap: £1.35b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Share buyback programme

1 Aug 2023 07:00

RNS Number : 8078H
Chemring Group PLC
01 August 2023
 

FOR IMMEDIATE RELEASE 1 AUGUST 2023

 

CHEMRING GROUP PLC ("Chemring" or "the Group")

COMMENCEMENT OF £50 MILLION SHARE BUYBACK PROGRAMME

 

Chemring is pleased to announce the commencement of a Share Buyback Programme (the "Buyback Programme") with effect from 1 August 2023 to purchase ordinary shares of 1 pence each ("Ordinary Shares") in the capital of the Company up to a maximum aggregate consideration payable by the Company of £50 million.

The Group's disciplined approach to capital allocation, which is reviewed by the Board on a regular basis, prioritises both organic and inorganic investment, a growing and sustainable dividend, and a prudent approach to leverage.

 

The Company has a strong balance sheet, with leverage of 0.3x net debt to EBITDA at 30 April 2023, and a robust pipeline of organic and inorganic investment opportunities. The Board believes that the Buyback Programme, by reducing the Company's share capital, will facilitate an improved capital structure and deliver value for shareholders, whilst still maintaining a strong balance sheet.

 

The Buyback Programme is consistent with the Group's approach to capital allocation and reflects the Board's continued confidence in the future prospects of the Group.  The Group intends to continue assessing other organic and inorganic investment opportunities for the duration of the buyback, in line with the Group's wider growth strategy.

 

The sole purpose of the Buyback Programme is to reduce the Company's share capital and it is intended that Ordinary Shares purchased shall be cancelled. The Buyback Programme will end on 31 July 2024.

 

The Group will seek to make market purchases of Ordinary Shares at a price or prices that the Group deems to be good value for shareholders. In accordance with the Company's general authority to repurchase Ordinary Shares granted by its shareholders at the Annual General Meeting held on 15 March 2023 (the "General Authority"), the Buyback Programme will purchase no more than 28,358,308 Ordinary Shares. 

 

Any purchases of Ordinary Shares by Chemring in relation to the Buyback Programme will be conducted in accordance with: the General Authority; any further approvals to purchase shares as may be granted by its shareholders from time to time; the Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (as amended); and Chapter 12 of the Listing Rules.

 

The Company has entered into an irrevocable, non-discretionary instruction with Investec Bank plc ("Investec") to conduct the Buyback Programme on its behalf and to make trading decisions under the Buyback Programme independently of the Company. The Company has a right to terminate this instruction subject to being in compliance with certain regulatory conditions.

 

The Company will make further announcements in due course following the completion of any repurchases. There is no guarantee that the Buyback Programme will be implemented in full or that any Ordinary Shares will be repurchased by the Company. The Buyback Programme will not impact the Company's existing Ordinary Share dividend policy, which will continue unaffected through the regular awards of interim and final dividends.

 

At the time of this announcement, the Company's share capital comprises 283,609,773 Ordinary Shares with voting rights and 62,500 cumulative preference shares with no voting rights, save in specified limited circumstances. The total number of voting rights in the Company is therefore 283,609,773.

 

Michael Ord, Group Chief Executive of Chemring, commented:

 

"In recent years Chemring has been focused on building a stronger, higher quality and more resilient business, in doing so it has built a strong and deployable balance sheet which has provided the Group with increased optionality. The share buyback programme of up to £50m that we have announced today provides us with additional flexibility to deliver value for our shareholders and to our commitment to balance near-term performance with longer-term growth and value creation."

 

-ENDS-

 

For further information:

 

Rupert Pittman Group Director of Corporate Affairs, 01794 463401

Chemring Group PLC

 

James McFarlane MHP Communications 020 3128 8100

Ollie Hoare

 

Notes to editors

 

· Chemring is a FTSE-250 global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,600 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under two strategic product segments: Sensors & Information and Countermeasures & Energetics

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

 

www.chemring.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSUARBROVUBOAR
Date   Source Headline
3rd Jun 20264:00 pmRNSHolding(s) in Company
2nd Jun 20267:02 amRNSDirectorate change
2nd Jun 20267:00 amRNSInterim results
1st Jun 20267:00 amRNSTotal Voting Rights
28th May 20262:36 pmRNSHolding(s) in Company
22nd May 20269:15 amRNSHolding(s) in Company
21st May 20267:00 amRNSHolding(s) in Company
14th May 20267:00 amRNSHolding(s) in Company
1st May 20267:00 amRNSHolding(s) in Company
1st May 20267:00 amRNSTotal Voting Rights
1st Apr 20267:00 amRNSTotal Voting Rights
31st Mar 20263:46 pmRNSDirector/PDMR Shareholding
19th Mar 202611:00 amRNSHolding(s) in Company
4th Mar 20267:00 amRNSAppointment of non-executive director
2nd Mar 20269:15 amRNSTotal Voting Rights
20th Feb 20262:48 pmRNSResult of AGM
20th Feb 20267:00 amRNSAGM Update
16th Feb 20267:00 amRNSHolding(s) in Company
9th Feb 20267:00 amRNSHolding(s) in Company
2nd Feb 20267:00 amRNSTotal Voting Rights
23rd Jan 20264:41 pmRNSDirector/PDMR Shareholding
12th Jan 20261:35 pmRNSNotice of AGM
2nd Jan 202610:29 amRNSTotal Voting Rights
19th Dec 202511:53 amRNSHolding(s) in Company
19th Dec 202511:53 amRNSHolding(s) in Company
18th Dec 20257:00 amRNSBlock listing Interim Review
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:00 amRNSDirector/PDMR Shareholding
15th Dec 20258:42 amRNSTransaction in Own Shares
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20253:01 pmRNSAdditional Listing - Replacement
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 202512:41 pmRNSDirector/PDMR Shareholding
10th Dec 202512:40 pmRNSDirector/PDMR Shareholding
10th Dec 202512:40 pmRNSDirector/PDMR Shareholding
10th Dec 202512:38 pmRNSDirector/PDMR Shareholding
10th Dec 202512:36 pmRNSDirector/PDMR Shareholding
10th Dec 202512:36 pmRNSDirector/PDMR Shareholding
10th Dec 20257:00 amRNSAdditional Listing
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20254:23 pmRNSDirector/PDMR Shareholding
9th Dec 20257:00 amRNSResults for the year ended 31 October 2025
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.